ABX 464

Product Description

ABX 464 is an HIV RNA splicing modulator; it selectively enhances the splicing of HIV RNA in infected human PBMCs and inhibits viral replication, with no global effect on cellular splicing. ABX 464 inhibits replication of HIV strains harboring mutations associated with drug-resistance. ABX 464 binds the cap binding complex (CBC) and upregulates miR-124 expression in vitro and decreases expression of miR-124 target genes, MCP-1, CXCL-1, SERPIN-E1 in macrophages. It also decreases the number of Th17 cells, as well as IL-6 soluble receptor in CD4+ T cells. In HIV infected humanized mice, treatment with ABX 464 reduces viral load. Anti-inflammatory.

Solubility

Preparing Stock Solutions for ABX 464

The following data is based on the product molecular weight 338.71

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.95 mL	14.76 mL	29.52 mL
5 mM	0.59 mL	2.95 mL	5.90 mL
10 mM	0.30 mL	1.48 mL	2.95 mL
50 mM	0.06 mL	0.30 mL	0.59 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Vautrin Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing. Sci.Rep. 2018 PMID: 30692590
• Campos Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis. Retrovirology 2015 PMID: 25889234